TOKYO, Mar 25 (Pulse News Wire) – Sumitomo Pharma CO.,LTD. (4506.T) reported non-operating revenue for its fiscal year ending March 31, 2026.
The company recorded dividend income of ¥48.34 billion as part of interest and dividend income (non-operating revenue) due to a decision made by its subsidiary, Sumitomo Pharma Switzerland GmbH, to distribute dividends. This non-operating revenue will not impact the consolidated profit and loss statement.
The dividend received will be eliminated in the consolidation process, ensuring no effect on the overall financial performance. Sumitomo Pharma emphasized that forward-looking statements included in this press release are based on assumptions and judgments derived from available information as of the announcement date.
These predictions involve inherent risks and uncertainties, which could lead to significant differences from the projections outlined in this release due to various factors.
🟢 Confidence: High AI-translated content.